{"prompt": "['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'After the study is completed at a given site, the electronic data collection tool will be', 'taken off-line to prevent the entry of new data or changes to existing data.', 'If a site receives a report of a new SAE from a study participant or receives updated', 'data on a previously reported SAE after the electronic data collection tool has been', 'taken off-line, then the site can report this information on a paper SAE form (see', 'next section) or to the medical monitor/SAE coordinator by telephone.', 'Contacts for SAE reporting can be found in the SRM.', '70']['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.5.', 'Appendix 5: Contraceptive Guidance and Collection of', 'Pregnancy Information', 'Definitions', 'Woman of Childbearing Potential (WOCBP)', 'A woman is considered fertile following menarche and until becoming post-menopausal', 'unless permanently sterile (see below)', 'Women in the following categories are not considered WOCBP', '1. Premenarchal', '2. Premenopausal female with ONE of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', \"Note: Documentation can come from the site personnel's: review of participant's\", 'medical records, medical examination, or medical history interview.', '3. Postmenopausal female', 'A postmenopausal state is defined as no menses for 12 months without an', 'alternative medical cause. A high follicle stimulating hormone (FSH) level in', 'the postmenopausal range may be used to confirm a postmenopausal state in', 'women not using hormonal contraception or hormonal replacement therapy', '(HRT). However, in the absence of 12 months of amenorrhea, a single FSH', 'measurement is insufficient and confirmatory testing with additional FSH and', 'estradiol measurements is required.', 'Females on HRT and whose menopausal status is in doubt will be required to', 'use one of the non-hormonal highly effective contraception methods if they wish', 'to continue their HRT during the study. Otherwise, they must discontinue HRT', 'to allow confirmation of postmenopausal status before study enrollment.', 'Pregnancy Testing', 'WOCBP should only be included after a confirmed menstrual period and a negative', 'highly sensitive urine or serum pregnancy test', 'Additional pregnancy testing will be performed at approximately monthly intervals', 'during the study treatment period, after the last dose of study treatment and as', 'required locally.', 'Pregnancy testing will be performed whenever a menstrual cycle is missed or when', 'pregnancy is otherwise suspected', '71']['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Pregnancy testing, with a high sensitivity test will be performed using the test kit', 'provided by the central laboratory and approved by the sponsor and in accordance', 'with instructions provided in the test kit package insert.', 'Collection of Pregnancy Information', 'Male participants with partners who become pregnant', 'Investigator will not routinely attempt to collect pregnancy information on any male', \"participant's female partner(s) who becomes pregnant while the male participant is\", 'participating in this study; however, voluntary reports of such incidents will be', 'captured through the GSK standard reporting mechanism. This applies only to male', 'participants who receive double-blind study treatment.', \"If pregnancy information for a male participant's female partner(s) is voluntarily\", 'reported, after obtaining the necessary signed informed consent from the pregnant', 'female partner directly, the investigator will record pregnancy information on the', \"appropriate form and submit it to GSK within 24 hours of learning of the partner's\", 'pregnancy.', 'Partner will also be followed to determine the outcome of the pregnancy.', 'Information on the status of the mother and child will be forwarded to GSK', 'Generally, follow-up will be no longer than 6 to 8 weeks following the estimated', 'delivery date. Any termination of the pregnancy will be reported regardless of fetal', 'status (presence or absence of anomalies) or indication for procedure', 'Female Participants who become pregnant', 'Investigator will collect pregnancy information on any female participant, who', 'becomes pregnant while participating in this study.', 'Information will be recorded on the appropriate form and submitted to GSK within', \"24 hours of learning of a participant's pregnancy.\", 'Participant will be followed to determine the outcome of the pregnancy. The', 'investigator will collect follow up information on participant and neonate, which will', 'be forwarded to GSK Generally, follow-up will not be required for longer than 6 to 8', 'weeks beyond the estimated delivery date.', 'Any termination of pregnancy will be reported, regardless of fetal status (presence or', 'absence of anomalies) or indication for procedure.', 'While pregnancy itself is not considered to be an AE or SAE, any pregnancy', 'complication or elective termination of a pregnancy will be reported as an AE or', 'SAE.', 'A spontaneous abortion is always considered to be an SAE and will be reported as', 'such.', 'Any SAE occurring as a result of a post-study pregnancy which is considered', 'reasonably related to the study treatment by the investigator, will be reported to GSK', 'as described in Appendix 4. While the investigator is not obligated to actively seek', '72']\n\n###\n\n", "completion": "END"}